

ANZHFR Data Dictionary v16: Summary of changes

The changes to the ANZHFR Data Dictionary will apply to patients admitted from **1 January 2024**

Version	Variable #	Description of Change	Previous Value v15	Changes or Additions in v16
16	1.18 Patient Level Audit	Individual Health Identifier Addition of Individual Health Identifier (where available) which will enable linkage with administrative datasets such as the National Death Index, Pharmaceutical Benefits Scheme (PBS), Residential Aged Care	Not applicable	New variable added 1 January 2024 For collection in Australia only, where available
16	Date variables	Date variables	Date variables left blank if they are unknown	Previously 01011900 entered
16	2.12 Patient Level Audit	Pain assessment Variable retired 31 December 2023	1 Documented assessment of pain within 30 minutes of ED presentation 2 Documented assessment of pain greater than 30 minutes of ED presentation 3 Pain assessment not documented or not done 9 Not known	Variable retired 31 December 2023. No longer for collection in line with the updated Hip Fracture Clinical Care Standard quality indicators
16	2.15 Patient Level Audit	Transferred patients only: Nerve block before transfer New variable added 1 January 2024	Not applicable	New variable added 1 January 2024 to monitor performance against Hip Fracture Clinical Care Standard Indicator 2b <i>Did the patient with a hip fracture who was transferred from another hospital for treatment receive a nerve block prior to transfer?</i> 1 No 2 Yes 9 Not known
16	3.06 Patient Level Audit	Bone protection medication at admission Update to coding frame and data dictionary comments		<ul style="list-style-type: none"> Change to coding frame to include raloxifene and HRT <i>Yes - bisphosphonates, denosumab, romosozumab, teriparatide, raloxifene or HRT (with or without calcium and/or vitamin D)</i> Change to DD comments A patient is to be considered as 'taking' osteoporosis specific treatment if: <ul style="list-style-type: none"> Oral bisphosphonates, prescribed in the last 12 weeks. Zoledronate, administered in the last 24 months. Denosumab, administered the last 6 months. Teriparatide, administered in the last 7 days. Romosozumab, administered in the last month. These medications may be prescribed with or without calcium and / or vitamin D.

Version	Variable #	Description of Change	Previous Value v15	Changes or Additions in v16
16	3.13 Patient Level Audit	Clinical Frailty Scale Change to coding frame	1 Very Fit 2 Well 3 Well, with treated comorbid disease 4 Vulnerable 5 Mildly frail 6 Moderately frail 7 Severely frail 8 Very severely frail 9 Terminally ill 99 Not known	1 Very Fit 2 Well 3 Well, with treated comorbid disease 4 Vulnerable 5 Mildly frail 6 Moderately frail 7 Severely frail 8 Very severely frail 9 Terminally ill 10 Frailty assessment using other validated tool 99 Not known
16	3.14 Patient Level Audit	Delirium assessment prior to surgery New variable added 1 January 2024	Not applicable	New variable added 1 January 2024 to enable the identification of delirium prior to surgery, in addition to the week after surgery <i>Following admission to hospital, delirium is assessed prior to surgery using a validated tool and recorded in the medical record</i> 1 Not assessed 2 Assessed and not identified 3 Assessed and identified 9 Not known
16	4.05 Patient Level Audit	Type of anaesthesia Change to coding frame	1 General anaesthesia 5 Spinal / regional anaesthesia 6 General and spinal / regional anaesthesia 97 Other 99 Not known	Removal of regional anaesthesia from coding frame, as this is captured under 4.06 Analgesia- Nerve block 1 General anaesthesia 2 Spinal anaesthesia 3 General and spinal anaesthesia 97 Other 99 Not known
16	4.11 Patient Level Audit	First day mobilisation Variable retired 31 December 2023	0 Patient given opportunity to start mobilising day 1 post surgery 1 Patient not given opportunity to start mobilising day 1 post surgery 9 Not known	No longer for collection in line with the updated Hip Fracture Clinical Care Standard quality indicators Actual mobilisation after surgery is monitored at 4.19 First day walking

Version	Variable #	Description of Change	Previous Value v15	Changes or Additions in v16
16	4.16 Patient Level Audit	Bone protection medication at discharge from hospital Change to definition, coding frame and DD comments	What bone protection medication was the patient using at discharge from acute hospital? 0 No bone protection medication 1 Yes - Calcium and/or vitamin D only 2 Yes - Bisphosphonates, denosumab, romosozumab or teriparatide (with or without calcium and/or vitamin D) 9 Not known	Change to question and coding frame What bone protection medication was the patient taking at discharge from hospital? 0 No bone protection medication 1 Yes - Calcium and/or vitamin D only 2 Yes - Bisphosphonates, denosumab, romosozumab, teriparatide, raloxifene or HRT (with or without calcium and/or vitamin D) 3 No but received prescription at separation from hospital 9 Not known Change to DD comments A patient is to be considered as 'taking' osteoporosis specific treatment if: <ul style="list-style-type: none"> - Oral bisphosphonates, prescribed in the last 12 weeks. - Zoledronate, administered in the last 24 months. - Denosumab, administered the last 6 months. - Teriparatide, administered in the last 7 days. - Romosozumab, administered in the last month. These medications may be prescribed with or without calcium and / or vitamin D.
16	4.20 Patient Level Audit	Oral nutritional supplements New variable added 1 January 2024		New variable added 1 January 2024 to monitor performance against Hip Fracture Clinical Care Standard Indicator 3c Did the patient receive protein and energy oral nutritional supplements (ONS) during their admission? 0 No 1 Yes 9 Not known DD comments: ONS are defined as protein and energy nutrient-dense products purposed to increase dietary intake when diet alone is likely to be inadequate to meet nutritional requirements. These may include energy and protein enriched drinks (e.g. milk, soy, protein-fortified juice flavours), powders, soups, and/or desserts. Documented patient-level evidence must be observed as evidence of receiving ONS. Examples include documentation in the patient's medical record (e.g. 'patient provided with high protein drink') or patient-specific food services system/menu orders, documentation in the medication chart or food and fluid charts.

Version	Variable #	Description of Change	Previous Value v15	Changes or Additions in v16
16	7.07 Patient Level Audit	Bone protection medication at 120-day follow-up Change to coding frame and DD comments	What bone protection medication was the patient using at 120 days post-surgery? 0 No bone protection medication 1 Yes - Calcium and/or vitamin D only 2 Yes - Bisphosphonates, denosumab, romosozumab or teriparatide (with or without calcium and/or vitamin D) 9 Not known	Change to coding frame What bone protection medication was the patient using at 120 days post-surgery? 0 No bone protection medication 1 Yes - Calcium and/or vitamin D only 2 Yes - Bisphosphonates, denosumab, romosozumab, teriparatide, raloxifene or HRT (with or without calcium and/or vitamin D) 9 Not known Change to DD comments A patient is to be considered as 'taking' osteoporosis specific treatment if: <ul style="list-style-type: none"> - Oral bisphosphonates, prescribed in the last 12 weeks. - Zoledronate, administered in the last 24 months. - Denosumab, administered the last 6 months. - Teriparatide, administered in the last 7 days. - Romosozumab, administered in the last month. These medications may be prescribed with or without calcium and / or vitamin D.
16	Facility Level Audit	Retired 31 December 2023	The annual facility level audit collected information on an annual basis around the processes and models of care in place for people with a hip fracture.	Retired 31 December 2023